Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Endocrine. 2024 Jun;84(3):943-950. doi: 10.1007/s12020-024-03683-w. Epub 2024 Jan 16.
In recent years there has been a noticeable increase in the use of advanced hybrid closed-loop systems (AHCLs) for managing type 1 diabetes (T1D) among youth. However, there is a lack of comparison between the open-source automated insulin delivery (AID) system and the MiniMed™ 780 G system (780 G).
In this multi-center study, we retrospectively compared selected glycemic ranges of 26 individuals who used open-source AID and 20 individuals who used 780 G (age 11.3 years [IQR 9.3, 12.9] and 13.4 years [IQR 10.9, 16.5], respectively, p = 0.069) from system initiation to the most recent visit.
At baseline, the median HbA1c was significantly lower and the time below range (TBR) was significantly higher in the open-source AID group compared to the 780 G group (6.8% [IQR 6.4, 7.1] vs. 7.4% [IQR 6.9, 8.6], p = 0.006 and (1.0% [IQR 0.5, 2.8] vs. 0.0% [0.0, 1.0], p = 0.014), respectively; the median time in range (TIR) was similar (p = 0.068). After a median duration of 10.9 months on AHCLs the reduction of HbA1c was similar ( ~ 0.3%). The time spent in the hypoglycemic ranges was longer among users of the open-source AID compared to 780 G (TBR 4.2% [IQR 2.6, 7.3] vs. 2.0% [1.0, 4.0], p = 0.005) and TBR 1.1% [IQR 0.4, 2.3] vs. 0.0 [0.0, 1.0], p = 0.001).
Both AHCLs similarly improved HbA1c and TIR. The open-source AID youth had better glycemic control but spent longer time in the hypoglycemic range. These findings must be considered when choosing the use of AHCL technologies.
近年来,青少年使用先进的混合闭环系统(AHCLs)管理 1 型糖尿病(T1D)的情况明显增多。然而,开源自动胰岛素输送(AID)系统与 MiniMed™ 780G 系统(780G)之间缺乏比较。
在这项多中心研究中,我们回顾性比较了 26 名使用开源 AID 和 20 名使用 780G 的患者(年龄分别为 11.3 岁[IQR 9.3,12.9]和 13.4 岁[IQR 10.9,16.5],p=0.069)从系统启动到最近一次就诊的选定血糖范围。
在基线时,与 780G 组相比,开源 AID 组的 HbA1c 明显更低,血糖低于目标范围(TBR)的时间明显更长(6.8%[IQR 6.4,7.1] vs. 7.4%[IQR 6.9,8.6],p=0.006;(1.0%[IQR 0.5,2.8] vs. 0.0%[0.0,1.0],p=0.014),TIR 相似(p=0.068)。在使用 AHCL 中位数为 10.9 个月后,HbA1c 的降低幅度相似(~0.3%)。与 780G 相比,开源 AID 用户的低血糖范围时间更长(TBR 4.2%[IQR 2.6,7.3] vs. 2.0%[1.0,4.0],p=0.005;TBR 1.1%[IQR 0.4,2.3] vs. 0.0[0.0,1.0],p=0.001)。
两种 AHCL 均能显著改善 HbA1c 和 TIR。使用开源 AID 的青少年血糖控制更好,但处于低血糖范围的时间更长。在选择 AHCL 技术时,必须考虑到这些发现。